Calliditas Therapeutics appoints Frank Bringstrup as VP Regulatory Affairs
Calliditas Therapeutics AB (publ) (NASDAQ Stockholm: CALTX) (“Calliditas”) today announced the appointment of Dr. Frank Bringstrup as Vice President Regulatory Affairs effective February 1, 2019. As a member of the Management Team, Frank will have a leading role in the regulatory discussions and approval process of the company’s pivotal clinical phase 3 study NEFIGARD in patients with IgA nephropathy (IgAN).“I am delighted to welcome Frank to the team at this exciting stage in the company’s development. The combination of his strong experience in regulatory affairs, not only with the FDA